Opdivo (Nivolumab) vs Mektovi (binimetinib)

Opdivo (nivolumab) is an immunotherapy drug that works by blocking the PD-1 pathway, which can help the immune system recognize and attack cancer cells, and it is commonly used in various types of cancers, including melanoma, non-small cell lung cancer, and kidney cancer. Mektovi (binimetinib), on the other hand, is a targeted therapy that inhibits MEK proteins and is specifically used in combination with other drugs for the treatment of BRAF-mutated advanced melanoma. The choice between Opdivo and Mektovi would depend on the specific type of cancer, its molecular characteristics, such as the presence of a BRAF mutation, and the patient's overall health and treatment goals, which should be discussed with an oncologist.

Difference between Opdivo and Mektovi

Metric	Opdivo (Nivolumab)	Mektovi (binimetinib)
Generic name	Nivolumab	Binimetinib
Indications	Various types of cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, and others.	Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with encorafenib.
Mechanism of action	Programmed death receptor-1 (PD-1) blocking antibody.	MEK inhibitor, which works by inhibiting mitogen-activated protein kinase enzymes MEK1 and MEK2.
Brand names	Opdivo	Mektovi
Administrative route	Intravenous infusion	Oral
Side effects	Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, weakness, cough, dyspnea, decreased appetite, and others.	Fatigue, rash, nausea, abdominal pain, arthralgia, vomiting, and others.
Contraindications	Hypersensitivity to nivolumab or any of its excipients.	Hypersensitivity to binimetinib or any of its excipients.
Drug class	Immune checkpoint inhibitor, monoclonal antibody.	Antineoplastic agent, kinase inhibitor.
Manufacturer	Bristol-Myers Squibb	Array BioPharma Inc. (a subsidiary of Pfizer Inc.)

Efficacy

Opdivo (Nivolumab) in the Treatment of Skin Cancer

Opdivo, also known by its generic name Nivolumab, is a medication that has demonstrated efficacy in the treatment of skin cancer, specifically metastatic melanoma. As an immune checkpoint inhibitor, Opdivo works by blocking the PD-1 protein on T cells, which are a type of white blood cell that are part of the immune system. By inhibiting this protein, Opdivo enables the immune system to better detect and attack cancer cells. Clinical trials have shown that Opdivo can significantly improve survival rates in patients with advanced melanoma compared to traditional chemotherapy.

Moreover, Opdivo has been evaluated in various clinical settings, including as a first-line treatment and in combination with other therapies. Studies have indicated that when used in combination with another immune checkpoint inhibitor, such as ipilimumab, Opdivo can lead to improved outcomes in terms of progression-free survival and overall survival in patients with advanced melanoma. However, the benefits of combination therapy must be weighed against the increased risk of side effects.

Mektovi (Binimetinib) in the Management of Skin Cancer

Mektovi, with the generic name binimetinib, is another therapeutic agent used in the treatment of skin cancer, particularly unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Mektovi is a kinase inhibitor that works by targeting and inhibiting specific enzymes known as MEK1 and MEK2. These enzymes play a role in the MAPK/ERK pathway, which is involved in the growth and development of cancer cells. By inhibiting these enzymes, Mektovi can help to slow down or stop the growth of cancer cells.

The efficacy of Mektovi has been established in clinical trials, often in combination with other targeted therapies such as encorafenib, a BRAF inhibitor. This combination has been shown to improve overall survival and progression-free survival in patients with BRAF-mutated metastatic melanoma compared to BRAF inhibitor monotherapy. The combination of Mektovi and encorafenib represents a significant advancement in the targeted treatment approach for this subset of melanoma patients, offering a more personalized therapy option that can lead to better outcomes.

Regulatory Agency Approvals

Opdivo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Mektovi

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Opdivo or Mektovi today

If Opdivo or Mektovi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Opdivo

Buy Mektovi

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: